APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1

Area of Science:

• Oncology
• Immunology
• G protein-coupled receptor signaling

Background:

• Previous studies indicated Apelin receptor (APLNR) inhibits nasopharyngeal carcinoma (NPC) growth and metastasis.
• The role of APLNR in regulating PD-L1 expression and immune escape in NPC remains unelucidated.

Purpose of the Study:

• To investigate the role of APLNR in regulating PD-L1 expression and immune escape in NPC.
• To elucidate the underlying molecular mechanisms.
• To evaluate the therapeutic potential of targeting APLNR in combination with PD-L1 blockade.

Main Methods:

• Analysis of APLNR and PD-L1 expression and correlation in NPC tissues and cells.
• In vitro and in vivo investigation of APLNR's effect on PD-L1 expression and mechanism.
• Evaluation of combined APLNR targeting and PD-L1 antibody therapy in a nude mouse xenograft model.

Main Results:

• APLNR expression is negatively correlated with PD-L1 in NPC.
• APLNR inhibits PD-L1 by blocking the JAK1/STAT1 pathway via interaction with JAK1.
• APLNR enhances anti-tumor immunity by increasing IFN-γ secretion, CD8+ T-cell infiltration, and reducing T-cell apoptosis.
• Combination therapy of APLNR targeting and PD-L1 antibody demonstrated superior efficacy in inhibiting NPC growth in vivo.

Conclusions:

• APLNR plays a novel role in regulating PD-L1 expression and immune escape in NPC.
• APLNR represents a potential therapeutic target for enhancing NPC immunotherapy.